My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.
5 Biotech Stocks Worth Adding to Your Portfolio Now
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Best Biotech Stocks to Buy in 2025
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
3 Mid-Caps Worth Watching Closely in March
Mid-cap stocks don't get the same headlines as large caps but move aggressively in both directions, creating outsized opportunities for investors. Unlike their mega-cap counterparts, which tend to grind higher or lower over time, mid-caps often soar or crash within days, driven by headlines, sentiment, and pure speculation.
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics (AKRO -2.31%)is part of this group.
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
Shares of Akero Therapeutics (AKRO) doubled Monday when the pharmaceutical firm that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver disease.
Why did Akero (AKRO) stock soar 110% on Monday?
Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study.
